So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

Markey C. McNutt, MD, PhD; Zahid Ahmad, MD

Two proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have obtained approval by the United States Food and Drug Administration: evolocumab (Amgen) and alirocumab (Sanofi/Regeneron). Per their package inserts, both are “indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (FH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein-cholesterol (LDL-C).” Evolocumab has an additional indication for homozygous FH patients.

Several issues cloud the use of PCSK9 inhibitors in FH (also referred to as autosomal dominant hypercholesterolemia) patients and may be causing confusion for both clinicians and payers.

First, what does “maximally tolerated statin” refer to? It may be interpreted as no statin in patients with complete statin intolerance or it may imply high-intensity statin therapy (atorvastatin 40 or 80 mg daily and rosuvastatin 20 or 40 mg daily). Second, which patients require additional lowering of LDL-C? Recent guidelines de-emphasize LDL-C goals, although many clinicians likely continue to treat to LDL-C target levels. Third, how should FH be diagnosed? No standard FH diagnostic criteria—or even International Classification of Diseases-9 or -10 codes—exist in the United States. FH can get levels. Third, how should FH be diagnosed? No standard

From the Division of Pediatric Genetics & Metabolism (M.C.M.), and Division of Nutrition & Metabolic Diseases (Z.A.), Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Correspondence to Zahid Ahmad, MD, Division of Nutrition & Metabolic Diseases, Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Mail Code 8537, Dallas, TX 75390. E-mail Zahid.ahmad@utsouthwestern.edu

Circ Cardiovasc Genet. 2015;8:749-751. DOI: 10.1161/CIRCGENETICS.115.001256

© 2013 American Heart Association, Inc.
Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org
DOI: 10.1161/CIRCGENETICS.115.001256

In homozygous FH patients with biallelic null mutations, evolocumab fails to reduce LDL-C.1 Does something similar occur in heterozygous FH patients with PCSK9 mutations? PCSK9 mutations affect PCSK9’s affinity for the LDL receptor (LDLR). Could they also result in variable affinities for a PCSK9 monoclonal antibody?

Although studies of alirocumab and evolocumab have already been done in heterozygous FH patients, they did not require genetic screening for inclusion.2,3 In the current issue of Circulation: Cardiovascular Genetics, Hopkins et al4 describe the results of an interventional study of alirocumab (150 mg every 2 weeks) administered to 13 FH patients harboring PCSK9 gain-of-function mutations. The study represents the first such investigation in humans with gain-of-function PCSK9 mutations.

Alirocumab achieved 50% to 70% LDL-C reductions—with 12 of 13 patients getting to an LDL-C <70 mg/dL—similar to prior studies, including those of heterozygous FH patients (Figure).1,3,5,6 The high affinity of monoclonal antibodies to PCSK9 and the high therapeutic concentrations of antibody likely overwhelm any difference in affinity that a PCSK9 mutation may cause.

Clearly, as long as interference occurs in the PCSK9:LDLR interaction, a therapeutic response results. In fact, previous in vitro studies showed that mutant PCSK9 proteins can be blocked by a peptide that inhibits the PCSK9:LDLR interaction.7 Alirocumab seems safe for PCSK9 FH patients. No serious adverse events directly attributable to the study drug and no reports of myalgia or neurocognitive disorders—both of which have been noted in other studies4,6—occurred.

A few questions still remain. Will evolocumab have similar efficacy for PCSK9 FH patient? It has a different epitope and, thus, the potential exists for variable affinity to mutant PCSK9. Also, the study by Hopkins et al lacks comparator groups of FH patients with LDLR or apolipoprotein B (APOB) mutations, so no direct comparison of the efficacy of PCSK9 monoclonal antibodies has been reported thus far.

More than 10 variants are associated with FH, with the p.S127R and p.D374Y mutations being most studied functionally. The aspartic acid residue at position 374 lies in the binding interface between the LDLR and PCSK9, and its substitution to tyrosine results in increased affinity between PCSK9 and LDLR at the cell surface. The substitution of serine residue at position 127 to arginine does not affect binding affinity at the cell surface; how it results in downregulation of LDLR from the surface remains unclear.

Because of the rarity of gain-of-function PCSK9 mutations (<2% of genetic hypercholesterolemias’), few descriptions exist of their phenotype, especially in comparison with the more common genetic causes of FH (LDLR and APOB).

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Division of Pediatric Genetics & Metabolism (M.C.M.), and Division of Nutrition & Metabolic Diseases (Z.A.), Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.

Correspondence to Zahid Ahmad, MD, Division of Nutrition & Metabolic Diseases, Center for Human Nutrition, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Mail Code 8537, Dallas, TX 75390. E-mail Zahid.ahmad@utsouthwestern.edu

Circ Cardiovasc Genet. 2015;8:749-751. DOI: 10.1161/CIRCGENETICS.115.001256

© 2013 American Heart Association, Inc.
Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org
DOI: 10.1161/CIRCGENETICS.115.001256
Previous studies with a single gain-of-function mutation in\textit{PCSK9} (D374Y) have noted higher levels of LDL-C and earlier onset of coronary heart disease than heterozygous mutations in either \textit{LDLR} or \textit{APOB}.

Hopkins et al\(^9\) assembled clinical characteristics of the largest cohort (n=160) to date of patients with FH-causing \textit{PCSK9} mutations. A few issues may limit the interpretation of their data. Controls were not selected from the same population as cases; because coronary heart disease rates vary throughout the world, some bias may have been introduced into their analysis of premature coronary heart disease. Also, some of the mutations had LDL-C levels lower than typical for FH (156 mg/dL in 6 patients with Pro71Leu mutations from the Netherlands, for example) making it unclear whether these are true disease-causing mutations.

Overall, it seems that \textit{PCSK9} gain-of-function mutations cause more severe hypercholesterolemia than \textit{LDLR} mutations. Such information may be useful for ongoing FH genetic screening studies\(^10\) and future bio-banking efforts, where sequencing of \textit{PCSK9} can be reserved for patients with the highest LDL-C who lack any mutations in \textit{LDLR} or \textit{APOB}.

Although several questions remain unanswered about the use of PCSK9 inhibitors, they seem safe and efficacious at lowering LDL-C levels in most patients, regardless of the underlying genetics. Of course, the results of ongoing cardiovascular outcome studies will ultimately have the largest effect on both prescriber and payer practices.

**Acknowledgments**

We thank Curtis and Stacy Lane (from the FH Foundation) and Abhimanyu Garg, MD, for their thoughtful discussions and guidance in preparing this editorial.

**Disclosures**

Dr Ahmad has received honorarium for educational talks sponsored by Sanofi, is on speakers’ bureaus for Amgen and Genzyme, and participated in advisory board meetings sponsored by Genzyme and Regeneron. The other author reports no conflicts.

**References**


**Key Words:** Editorials ◼ cardiovascular disease ◼ familial hypercholesterolemia ◼ hypercholesterolemia ◼ LDLR ◼ lipoprotein ◼ PCSK9 ◼ pharmacology ◼ treatment
So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients
Markey C. McNutt and Zahid Ahmad

_Circ Cardiovasc Genet._ 2015;8:749-751
doi: 10.1161/CIRCGENETICS.115.001256
_Circulation: Cardiovascular Genetics_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 1942-325X. Online ISSN: 1942-3268

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circgenetics.ahajournals.org/content/8/6/749

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Genetics_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

**Reprints:** Information about reprints can be found online at:
http://www.lww.com/reprints

**Subscriptions:** Information about subscribing to _Circulation: Cardiovascular Genetics_ is online at:
http://circgenetics.ahajournals.org//subscriptions/